Abstract
Our current understanding of cancer suggests that every tumour has individual features. Approaches to cancer treatment require thorough comprehension of the mechanisms triggering genomic instability and protecting cancer cells from therapeutic treatments. Base excision repair (BER) is a frontline DNA repair system that is responsible for maintaining genome integrity. The BER pathway prevents the occurrence of disease, including cancer, by constantly repairing DNA base lesions and DNA single strand breaks caused by endogenous and exogenous mutagens. BER is an important DNA repair system for cancer cell survival, as it can affect both chemoand radio-resistance of tumours. Variations in BER capacity are likely responsible for a number of cases of sporadic cancer and may also modulate cancer sensitivity and resistance to therapeutic treatments. For these reasons, it is broadly accepted that targeting BER enzymes might be a promising approach to personalised anti-cancer therapy. However, recent advances in both treatment strategies and the comprehension of cancer development call for a better understanding of the consequences of BER inhibition. Indeed, the impact on both the tumour microenvironment and healthy tissues is still unclear. This review will summarise the current status of the approaches exploiting BER targeting, describing the most promising small molecule inhibitors and synthetic lethality strategies, as well as potential limitations of these approaches.
Keywords: Base Excision Repair, Inhibitors, DNA Damage, Cancer, enzymes, anti-cancer therapy.
Current Pharmaceutical Design
Title:DNA Base Excision Repair: The Achilles' Heel of Tumour Cells and their Microenvironment?
Volume: 23 Issue: 32
Author(s): Mattia Poletto *, Arnaud J. Legrand *Grigory L. Dianov*
Affiliation:
- CRUK and MRC Oxford Institute for Radiation Oncology, University of Oxford, Department of Oncology, Old Road Campus Research Building, OX37DQ Oxford,United Kingdom
- CRUK and MRC Oxford Institute for Radiation Oncology, University of Oxford, Department of Oncology, Old Road Campus Research Building, OX37DQ Oxford,United Kingdom
- CRUK and MRC Oxford Institute for Radiation Oncology, University of Oxford, Department of Oncology, Old Road Campus Research Building, OX37DQ Oxford,United Kingdom
Keywords: Base Excision Repair, Inhibitors, DNA Damage, Cancer, enzymes, anti-cancer therapy.
Abstract: Our current understanding of cancer suggests that every tumour has individual features. Approaches to cancer treatment require thorough comprehension of the mechanisms triggering genomic instability and protecting cancer cells from therapeutic treatments. Base excision repair (BER) is a frontline DNA repair system that is responsible for maintaining genome integrity. The BER pathway prevents the occurrence of disease, including cancer, by constantly repairing DNA base lesions and DNA single strand breaks caused by endogenous and exogenous mutagens. BER is an important DNA repair system for cancer cell survival, as it can affect both chemoand radio-resistance of tumours. Variations in BER capacity are likely responsible for a number of cases of sporadic cancer and may also modulate cancer sensitivity and resistance to therapeutic treatments. For these reasons, it is broadly accepted that targeting BER enzymes might be a promising approach to personalised anti-cancer therapy. However, recent advances in both treatment strategies and the comprehension of cancer development call for a better understanding of the consequences of BER inhibition. Indeed, the impact on both the tumour microenvironment and healthy tissues is still unclear. This review will summarise the current status of the approaches exploiting BER targeting, describing the most promising small molecule inhibitors and synthetic lethality strategies, as well as potential limitations of these approaches.
Export Options
About this article
Cite this article as:
Poletto Mattia *, Legrand J. Arnaud*, Dianov L. Grigory*, DNA Base Excision Repair: The Achilles' Heel of Tumour Cells and their Microenvironment?, Current Pharmaceutical Design 2017; 23 (32) . https://dx.doi.org/10.2174/1381612823666170710123602
DOI https://dx.doi.org/10.2174/1381612823666170710123602 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives
Current Drug Targets Molecular Design and Medicinal Applications of Nano-Nitric Oxide Delivery Systems
Current Medicinal Chemistry Metabolic Drug Interactions Between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract
Current Drug Metabolism Meet Our Editorial Board Member:
Current Drug Targets Analysis of Comparative Proteomic and Potent Targets of Peniciketal A in Human Acute Monocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Phosphorylation Processes Controlling Aromatase Activity in Br east Cancer: An Update
Mini-Reviews in Medicinal Chemistry Impact of Opioid Receptor, Mu 1 (OPRM1) Polymorphisms on Pain Sensitivity and Clinical Response to Opioid Analgesic Therapy
Current Pharmacogenomics and Personalized Medicine Biologics in Polymyositis and Dermatomyositis-Associated Interstitial Lung Disease
Current Pharmaceutical Biotechnology Epithelial Organotypic Cultures: A Viable Model to Address Mechanisms of Carcinogenesis by Epitheliotropic Viruses
Current Topics in Medicinal Chemistry The Role of Cellular Plasticity in Cancer Development
Current Medicinal Chemistry Graphical Abstracts:
Current Organic Chemistry The Effects of Bisphosphonates on the Bone Marrow Niche and Circulating and Disseminated Tumor Cells
Current Cancer Therapy Reviews Overview of Naphthalimide Analogs as Anticancer Agents
Current Medicinal Chemistry Serum Free or Not: Two Distinct Recycling Mechanisms Mediated by Alpha v Beta 3 Integrin
Current Pharmaceutical Biotechnology EZH2 RIP-seq Identifies Tissue-specific Long Non-coding RNAs
Current Gene Therapy It Takes Two to Tango: The Structure and Function of LIM, RING, PHD and MYND Domains
Current Pharmaceutical Design Notch Signaling: A Potential Therapeutic Target in Prostate Cancer
Current Cancer Drug Targets Cancer Resistance to Type II Topoisomerase Inhibitors
Current Medicinal Chemistry Embryonic Stem Cells or Induced Pluripotent Stem Cells? A DNA Integrity Perspective
Current Gene Therapy Application of Synchrotron Radiation in Mammography
Recent Patents on Medical Imaging